首页 > 最新文献

Enzymes最新文献

英文 中文
The peptidomimetic approach for the design of viral protease inhibitors. 病毒蛋白酶抑制剂设计的拟肽方法。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2025-01-01 Epub Date: 2025-07-23 DOI: 10.1016/bs.enz.2025.06.007
Andrea Trabocchi

The transformation of peptides into drug leads is an established approach in medicinal chemistry and drug discovery. Peptidomimetics are designed to mimic the bioactivity of peptides while addressing their limitations, such as poor metabolic stability and low bioavailability, thus resulting in improved receptor affinity and selectivity. Over last decades, a range of synthetic strategies has emerged to improve the pharmacological properties of these molecules through local and global conformational restrictions and introducing secondary structure mimetics. Herein the essential tools and methodologies in peptidomimetic design are reported with highlights to their therapeutic relevance, particularly in antiviral drug development. Peptidomimetics have shown notable success in targeting viral proteases as key enzymes involved in the life cycle of several pathogenic viruses. Case studies involving peptidomimetic inhibitors of HIV protease, HCV NS3/4A protease, SARS-CoV-2 main protease (3CLpro), and the NS2B-NS3 proteases of Zika and Dengue viruses are reported highlighting the efficacy of this approach, emphasizing the potential of peptidomimetic drugs as powerful tools in the treatment of infectious diseases.

多肽转化为药物先导是药物化学和药物发现的一种既定方法。肽模拟物旨在模拟肽的生物活性,同时解决其局限性,如代谢稳定性差和生物利用度低,从而提高受体亲和力和选择性。在过去的几十年里,一系列的合成策略已经出现,通过局部和全局构象限制和引入二级结构模拟物来改善这些分子的药理学性质。本文报道了拟肽设计的基本工具和方法,并强调了它们的治疗相关性,特别是在抗病毒药物开发方面。拟生肽在靶向病毒蛋白酶方面取得了显著的成功,这些酶是参与几种致病病毒生命周期的关键酶。HIV蛋白酶、HCV NS3/4A蛋白酶、SARS-CoV-2主蛋白酶(3CLpro)以及寨卡病毒和登革热病毒的NS2B-NS3蛋白酶的拟肽抑制剂的案例研究强调了这种方法的有效性,强调了拟肽药物作为治疗传染病的有力工具的潜力。
{"title":"The peptidomimetic approach for the design of viral protease inhibitors.","authors":"Andrea Trabocchi","doi":"10.1016/bs.enz.2025.06.007","DOIUrl":"https://doi.org/10.1016/bs.enz.2025.06.007","url":null,"abstract":"<p><p>The transformation of peptides into drug leads is an established approach in medicinal chemistry and drug discovery. Peptidomimetics are designed to mimic the bioactivity of peptides while addressing their limitations, such as poor metabolic stability and low bioavailability, thus resulting in improved receptor affinity and selectivity. Over last decades, a range of synthetic strategies has emerged to improve the pharmacological properties of these molecules through local and global conformational restrictions and introducing secondary structure mimetics. Herein the essential tools and methodologies in peptidomimetic design are reported with highlights to their therapeutic relevance, particularly in antiviral drug development. Peptidomimetics have shown notable success in targeting viral proteases as key enzymes involved in the life cycle of several pathogenic viruses. Case studies involving peptidomimetic inhibitors of HIV protease, HCV NS3/4A protease, SARS-CoV-2 main protease (3CLpro), and the NS2B-NS3 proteases of Zika and Dengue viruses are reported highlighting the efficacy of this approach, emphasizing the potential of peptidomimetic drugs as powerful tools in the treatment of infectious diseases.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"58 ","pages":"93-128"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trypanosoma cruzi and Leishmania spp. CAs. 克氏锥虫和利什曼原虫。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2025-01-01 Epub Date: 2025-07-16 DOI: 10.1016/bs.enz.2025.05.003
Alane Beatriz Vermelho, Felipe Raposo P Mansoldo, Veronica Silva Cardoso, Kamila Marques Sette, Claudiu T Supuran, Igor Almeida Rodrigues

Neglected tropical diseases (NTDs) such as Chagas disease and leishmaniasis represent significant public health challenges due to limited therapeutic options and the emergence of drug-resistant parasites. This chapter explores the potential of carbonic anhydrases (CAs) as novel drug targets in Trypanosoma cruzi and Leishmania spp., two etiologic agents of these diseases. The α-class CA in T. cruzi (TcCA) and the β-class CA in Leishmania donovani chagasi (LdcCA) have been functionally characterized and play essential roles in parasite metabolism, pH regulation, and survival. Several inhibitors, such as sulfonamides, thiols, hydroxamates, and benzoxaboroles, demonstrate potent enzymatic inhibition with promising selectivity over human isoforms. Advances in drug formulation, including nanoemulsions, have enhanced the bioavailability and efficacy of certain compounds. The chapter also discusses structure-activity relationships (SAR), challenges in translating in vitro potency to in vivo efficacy, and the strategic advantages of targeting parasite-specific CAs in combination therapies. These findings support CAs as viable and selective targets for innovative anti-parasitic drug development.

由于治疗选择有限和出现耐药寄生虫,恰加斯病和利什曼病等被忽视的热带病构成了重大的公共卫生挑战。本章探讨了碳酸酐酶(CAs)作为克氏锥虫和利什曼原虫两种致病因子的新药物靶点的潜力。克氏t虫α-类CA (TcCA)和多诺瓦氏chagasi利什曼原虫β-类CA (LdcCA)已被功能鉴定,并在寄生虫代谢、pH调节和生存中发挥重要作用。一些抑制剂,如磺胺类、硫醇类、羟酸酯类和苯并恶唑类,表现出对人类同种异构体的有效酶抑制作用。药物配方的进步,包括纳米乳剂,提高了某些化合物的生物利用度和功效。本章还讨论了结构-活性关系(SAR),将体外效力转化为体内功效的挑战,以及针对寄生虫特异性CAs在联合治疗中的战略优势。这些发现支持CAs作为创新抗寄生虫药物开发的可行和选择性靶点。
{"title":"Trypanosoma cruzi and Leishmania spp. CAs.","authors":"Alane Beatriz Vermelho, Felipe Raposo P Mansoldo, Veronica Silva Cardoso, Kamila Marques Sette, Claudiu T Supuran, Igor Almeida Rodrigues","doi":"10.1016/bs.enz.2025.05.003","DOIUrl":"https://doi.org/10.1016/bs.enz.2025.05.003","url":null,"abstract":"<p><p>Neglected tropical diseases (NTDs) such as Chagas disease and leishmaniasis represent significant public health challenges due to limited therapeutic options and the emergence of drug-resistant parasites. This chapter explores the potential of carbonic anhydrases (CAs) as novel drug targets in Trypanosoma cruzi and Leishmania spp., two etiologic agents of these diseases. The α-class CA in T. cruzi (TcCA) and the β-class CA in Leishmania donovani chagasi (LdcCA) have been functionally characterized and play essential roles in parasite metabolism, pH regulation, and survival. Several inhibitors, such as sulfonamides, thiols, hydroxamates, and benzoxaboroles, demonstrate potent enzymatic inhibition with promising selectivity over human isoforms. Advances in drug formulation, including nanoemulsions, have enhanced the bioavailability and efficacy of certain compounds. The chapter also discusses structure-activity relationships (SAR), challenges in translating in vitro potency to in vivo efficacy, and the strategic advantages of targeting parasite-specific CAs in combination therapies. These findings support CAs as viable and selective targets for innovative anti-parasitic drug development.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"57 ","pages":"129-182"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug design of tyrosinase inhibitors. 酪氨酸酶抑制剂的药物设计。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-06-25 DOI: 10.1016/bs.enz.2024.06.001
Francesco Melfi, Simone Carradori, Arianna Granese, Amar Osmanović, Cristina Campestre

This copper-containing enzyme catalyzes the rate-limiting step for the melanin skin pigment bioproduction. Tyrosinase inhibitors can be exploited as skin whitening agents and food preservatives, opening new scenarios in food, cosmetics, agriculture and medicine. Despite the availability of natural inhibitors (hydroquinone, α-arbutin, kojic acid, retinoids, azelaic acid, resveratrol, caftaric acid, valonea tannin, chrysosplenetin and phenylethyl resorcinol), several synthetic compounds were proposed to overcome side effects and to improve the efficacy of natural agents. This chapter will gather the recent advances about synthetic tyrosinase inhibitors from the MedChem perspective, providing new suggestions for the scaffold-based design of innovative compounds.

这种含铜酶催化了黑色素皮肤色素生物生成的限速步骤。酪氨酸酶抑制剂可用作皮肤美白剂和食品防腐剂,为食品、化妆品、农业和医药领域开辟了新的前景。尽管存在天然抑制剂(对苯二酚、α-熊果苷、曲酸、维甲酸、壬二酸、白藜芦醇、茶杉酸、缬氨鞣、金丝桃素和苯乙基间苯二酚),但为了克服副作用和提高天然抑制剂的功效,人们提出了一些合成化合物。本章将从 MedChem 的角度收集有关合成酪氨酸酶抑制剂的最新进展,为基于支架设计创新化合物提供新的建议。
{"title":"Drug design of tyrosinase inhibitors.","authors":"Francesco Melfi, Simone Carradori, Arianna Granese, Amar Osmanović, Cristina Campestre","doi":"10.1016/bs.enz.2024.06.001","DOIUrl":"10.1016/bs.enz.2024.06.001","url":null,"abstract":"<p><p>This copper-containing enzyme catalyzes the rate-limiting step for the melanin skin pigment bioproduction. Tyrosinase inhibitors can be exploited as skin whitening agents and food preservatives, opening new scenarios in food, cosmetics, agriculture and medicine. Despite the availability of natural inhibitors (hydroquinone, α-arbutin, kojic acid, retinoids, azelaic acid, resveratrol, caftaric acid, valonea tannin, chrysosplenetin and phenylethyl resorcinol), several synthetic compounds were proposed to overcome side effects and to improve the efficacy of natural agents. This chapter will gather the recent advances about synthetic tyrosinase inhibitors from the MedChem perspective, providing new suggestions for the scaffold-based design of innovative compounds.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"56 ","pages":"111-134"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges for developing bacterial CA inhibitors as novel antibiotics. 开发细菌 CA 抑制剂作为新型抗生素所面临的挑战。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-07-03 DOI: 10.1016/bs.enz.2024.05.006
Claudiu T Supuran

Acetazolamide, methazolamide, ethoxzolamide and dorzolamide, classical sulfonamide carbonic anhydrase (CA) inhibitors (CAIs) designed for targeting human enzymes, were also shown to effectively inhibit bacterial CAs and were proposed for repurposing as antibacterial agents against several infective agents. CAs belonging to the α-, β- and/or γ-classes from pathogens such as Helicobacter pylori, Neisseria gonorrhoeae, vacomycin resistant enterococci (VRE), Vibrio cholerae, Mycobacterium tuberculosis, Pseudomonas aeruginosa and other bacteria were considered as drug targets for which several classes of potent inhibitors have been developed. Treatment of some of these pathogens with various classes of such CAIs led to an impairment of the bacterial growth, reduced virulence and for drug resistant bacteria, a resensitization to clinically used antibiotics. Here I will discuss the strategies and challenges for obtaining CAIs with enhanced selectivity for inhibiting bacterial versus human enzymes, which may constitute an important weapon for addressing the drug resistance to β-lactams and other clinically used antibiotics.

乙酰唑胺、甲唑酰胺、乙氧唑酰胺和多唑酰胺是经典的磺酰胺碳酸酐酶(CA)抑制剂(CAIs),设计用于靶向人类酶,结果表明它们也能有效抑制细菌的 CAs,并建议将它们重新用作抗菌剂,以对付几种感染性病原体。幽门螺杆菌、淋病奈瑟菌、耐醋霉素肠球菌(VRE)、霍乱弧菌、结核分枝杆菌、铜绿假单胞菌和其他细菌等病原体中属于 α-、β- 和/或 γ 类的 CAs 被认为是药物靶标,并已针对这些靶标开发出几类强效抑制剂。用各种类型的此类 CAIs 治疗其中一些病原体会导致细菌生长受阻、毒力减弱,对于耐药细菌来说,还会导致它们对临床使用的抗生素不再敏感。在这里,我将讨论获得抑制细菌酶和人类酶的选择性更强的 CAIs 的策略和挑战,这可能是解决对 β-内酰胺类和其他临床常用抗生素产生耐药性的重要武器。
{"title":"Challenges for developing bacterial CA inhibitors as novel antibiotics.","authors":"Claudiu T Supuran","doi":"10.1016/bs.enz.2024.05.006","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.05.006","url":null,"abstract":"<p><p>Acetazolamide, methazolamide, ethoxzolamide and dorzolamide, classical sulfonamide carbonic anhydrase (CA) inhibitors (CAIs) designed for targeting human enzymes, were also shown to effectively inhibit bacterial CAs and were proposed for repurposing as antibacterial agents against several infective agents. CAs belonging to the α-, β- and/or γ-classes from pathogens such as Helicobacter pylori, Neisseria gonorrhoeae, vacomycin resistant enterococci (VRE), Vibrio cholerae, Mycobacterium tuberculosis, Pseudomonas aeruginosa and other bacteria were considered as drug targets for which several classes of potent inhibitors have been developed. Treatment of some of these pathogens with various classes of such CAIs led to an impairment of the bacterial growth, reduced virulence and for drug resistant bacteria, a resensitization to clinically used antibiotics. Here I will discuss the strategies and challenges for obtaining CAIs with enhanced selectivity for inhibiting bacterial versus human enzymes, which may constitute an important weapon for addressing the drug resistance to β-lactams and other clinically used antibiotics.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"383-411"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-sulfonamide bacterial CA inhibitors. 非磺酰胺细菌 CA 抑制剂。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.enz.2024.06.007
Fabrizio Carta

Non-sulfonamide chemical moieties able to inhibit the bacterial (b) expressed Carbonic Anhydrases (CAs; EC 4.2.1.1) constitute an important alternative to the prototypic modulators discussed in Chapter 6, as give access to large and variegate chemical classes, also of the natural origin. This contribution reports the main classes of compounds profiled in vitro on the bCAs and thus may be worth developing for the validation process of this class of enzymes.

能够抑制细菌(b)表达的碳酸酐酶(CAs;EC 4.2.1.1)的非磺酰胺化学分子是第 6 章中讨论的原型调节剂的重要替代品,因为它们提供了大量不同的化学类别(也来自天然来源)。这篇论文报告了体外分析 bCAs 的主要化合物类别,因此可能值得开发用于该类酶的验证过程。
{"title":"Non-sulfonamide bacterial CA inhibitors.","authors":"Fabrizio Carta","doi":"10.1016/bs.enz.2024.06.007","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.06.007","url":null,"abstract":"<p><p>Non-sulfonamide chemical moieties able to inhibit the bacterial (b) expressed Carbonic Anhydrases (CAs; EC 4.2.1.1) constitute an important alternative to the prototypic modulators discussed in Chapter 6, as give access to large and variegate chemical classes, also of the natural origin. This contribution reports the main classes of compounds profiled in vitro on the bCAs and thus may be worth developing for the validation process of this class of enzymes.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"193-212"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carbonic anhydrases in bacterial pathogens. 细菌病原体中的碳酸酐酶。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-06-06 DOI: 10.1016/bs.enz.2024.05.007
Reygan E Braga, Fares Z Najar, Chelsea L Murphy, Marianna A Patrauchan

Carbonic anhydrases (CAs) catalyze the reversable hydration of carbon dioxide to bicarbonate placing them into the core of the biochemical carbon cycle. Due to the fundamental importance of their function, they evolved independently into eight classes, three of which have been recently discovered. Most research on CAs has focused on their representatives in eukaryotic organisms, while prokaryotic CAs received significantly less attention. Nevertheless, prokaryotic CAs play a key role in the fundamental ability of the biosphere to acquire CO2 for photosynthesis and to decompose the organic matter back to CO2. They also contribute to a broad spectrum of processes in pathogenic bacteria, enhancing their ability to survive in a host and, therefore, present a promising target for developing antimicrobials. This review focuses on the distribution of CAs among bacterial pathogens and their importance in bacterial virulence and host-pathogen interactions.

碳酸酐酶(CA)催化二氧化碳与碳酸氢盐的可逆水合作用,是生化碳循环的核心。由于其功能的根本重要性,它们独立进化成八类,其中三类是最近发现的。对 CAs 的研究大多集中在真核生物中的 CAs 代表,而原核生物中的 CAs 受到的关注要少得多。然而,原核 CAs 在生物圈获取二氧化碳进行光合作用和将有机物分解为二氧化碳的基本能力中发挥着关键作用。它们还对致病细菌的一系列过程做出了贡献,增强了它们在宿主体内的生存能力,因此是开发抗菌药物的一个前景广阔的目标。本综述重点介绍 CAs 在细菌病原体中的分布及其在细菌毒力和宿主-病原体相互作用中的重要性。
{"title":"Carbonic anhydrases in bacterial pathogens.","authors":"Reygan E Braga, Fares Z Najar, Chelsea L Murphy, Marianna A Patrauchan","doi":"10.1016/bs.enz.2024.05.007","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.05.007","url":null,"abstract":"<p><p>Carbonic anhydrases (CAs) catalyze the reversable hydration of carbon dioxide to bicarbonate placing them into the core of the biochemical carbon cycle. Due to the fundamental importance of their function, they evolved independently into eight classes, three of which have been recently discovered. Most research on CAs has focused on their representatives in eukaryotic organisms, while prokaryotic CAs received significantly less attention. Nevertheless, prokaryotic CAs play a key role in the fundamental ability of the biosphere to acquire CO<sub>2</sub> for photosynthesis and to decompose the organic matter back to CO<sub>2</sub>. They also contribute to a broad spectrum of processes in pathogenic bacteria, enhancing their ability to survive in a host and, therefore, present a promising target for developing antimicrobials. This review focuses on the distribution of CAs among bacterial pathogens and their importance in bacterial virulence and host-pathogen interactions.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"313-342"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural products as tyrosinase inhibitors. 天然产品作为酪氨酸酶抑制剂。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-06-25 DOI: 10.1016/bs.enz.2024.06.002
Aslınur Doğan, Suleyman Akocak

Tyrosinase is a crucial copper-containing enzyme involved in the production of melanin. Melasma, age spots, and freckles are examples of hyperpigmentation diseases caused by excess production of melanin. Inhibiting tyrosinase activity is a crucial method for treating these disorders along with various applications such as cosmetics, food technology, and medicine. Natural products have proven a rich source of tyrosinase inhibitors, with several molecules from plant, marine, and microbial sources showing potential inhibitory action. This chapter provides a complete overview of natural compounds that have been found as tyrosinase inhibitors, with emphasis on their structures, modes of action, and prospective applications.

酪氨酸酶是一种重要的含铜酶,参与黑色素的生成。黄褐斑、老年斑和雀斑都是黑色素生成过多导致的色素沉着疾病。抑制酪氨酸酶的活性是治疗这些疾病的重要方法,同时还可应用于化妆品、食品技术和医药等多个领域。事实证明,天然产品是酪氨酸酶抑制剂的丰富来源,来自植物、海洋和微生物的多种分子具有潜在的抑制作用。本章全面概述了已发现的酪氨酸酶抑制剂天然化合物,重点介绍了它们的结构、作用模式和应用前景。
{"title":"Natural products as tyrosinase inhibitors.","authors":"Aslınur Doğan, Suleyman Akocak","doi":"10.1016/bs.enz.2024.06.002","DOIUrl":"10.1016/bs.enz.2024.06.002","url":null,"abstract":"<p><p>Tyrosinase is a crucial copper-containing enzyme involved in the production of melanin. Melasma, age spots, and freckles are examples of hyperpigmentation diseases caused by excess production of melanin. Inhibiting tyrosinase activity is a crucial method for treating these disorders along with various applications such as cosmetics, food technology, and medicine. Natural products have proven a rich source of tyrosinase inhibitors, with several molecules from plant, marine, and microbial sources showing potential inhibitory action. This chapter provides a complete overview of natural compounds that have been found as tyrosinase inhibitors, with emphasis on their structures, modes of action, and prospective applications.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"56 ","pages":"85-109"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycobacterial β-carbonic anhydrases: Molecular biology, role in the pathogenesis of tuberculosis and inhibition studies. 分枝杆菌的β-碳酸酐酶:分子生物学、在结核病发病机制中的作用和抑制研究。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-08-06 DOI: 10.1016/bs.enz.2024.05.012
Jenny Parkkinen, Ratul Bhowmik, Martti Tolvanen, Fabrizio Carta, Claudiu T Supuran, Seppo Parkkila, Ashok Aspatwar

Mycobacterium tuberculosis (Mtb), which causes tuberculosis (TB), is still a major global health problem. According to the World Health Organization (WHO), TB still causes more deaths worldwide than any other infectious agent. Drug-sensitive TB is treatable using first-line drugs; treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB requires second- and third-line drugs. However, due to the long duration of treatment, the noncompliance of patients with different levels of resistance of Mtb to these drugs has worsened the situation. Previously developed anti-TB drugs targeted the replication machinery, protein synthesis, and cell wall biosynthesis pathways of Mtb. Therefore, novel drugs targeting alternate pathways crucial for the survival and pathogenesis of Mtb in the human host are needed. The genome of Mtb encodes three β-carbonic anhydrases (CAs) that are fundamental for pH homeostasis, hypoxia, survival, and pathogenesis. Recently, several studies have shown that the β-CAs of Mtb could be inhibited both in vitro and in vivo using small chemical molecules, suggesting that these enzymes could be novel targets for developing anti-TB compounds that are devoid of resistance by Mtb. In addition, homologs of β-CAs are absent in humans; therefore, drugs developed to target these enzymes might have minimal off-target effects. In this work, we describe the roles of β-CAs in Mtb and discuss bioinformatics and cheminformatics tools used in development and discovery of novel inhibitors of these enzymes. In addition, we summarize the in vitro and in vivo studies demonstrating that the β-CAs of Mtb are indeed druggable targets.

导致结核病(TB)的结核分枝杆菌(Mtb)仍然是一个重大的全球健康问题。根据世界卫生组织(WHO)的数据,结核病在全球造成的死亡人数仍然高于其他任何传染病。对药物敏感的结核病可使用一线药物进行治疗;对耐多药(MDR)和广泛耐药(XDR)结核病的治疗则需要二线和三线药物。然而,由于治疗时间较长,不同程度的耐药结核病患者对这些药物的不依从性使情况更加恶化。以前开发的抗结核药物针对的是 Mtb 的复制机制、蛋白质合成和细胞壁生物合成途径。因此,需要针对对 Mtb 在人类宿主中生存和发病至关重要的其他途径的新型药物。Mtb的基因组编码三种β-碳酸酐酶(CAs),它们是pH平衡、缺氧、生存和致病的基础。最近,一些研究表明,可以使用小化学分子在体外和体内抑制 Mtb 的 β-碳酸酐酶,这表明这些酶可能是开发对 Mtb 没有抗药性的抗结核化合物的新靶点。此外,人类体内不存在β-CAs的同源物;因此,针对这些酶开发的药物可能会产生最小的脱靶效应。在这项工作中,我们描述了β-CAs在Mtb中的作用,并讨论了在开发和发现这些酶的新型抑制剂时使用的生物信息学和化学信息学工具。此外,我们还总结了体外和体内研究,这些研究表明 Mtb 的 β-CAs 确实是可药用的靶标。
{"title":"Mycobacterial β-carbonic anhydrases: Molecular biology, role in the pathogenesis of tuberculosis and inhibition studies.","authors":"Jenny Parkkinen, Ratul Bhowmik, Martti Tolvanen, Fabrizio Carta, Claudiu T Supuran, Seppo Parkkila, Ashok Aspatwar","doi":"10.1016/bs.enz.2024.05.012","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.05.012","url":null,"abstract":"<p><p>Mycobacterium tuberculosis (Mtb), which causes tuberculosis (TB), is still a major global health problem. According to the World Health Organization (WHO), TB still causes more deaths worldwide than any other infectious agent. Drug-sensitive TB is treatable using first-line drugs; treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB requires second- and third-line drugs. However, due to the long duration of treatment, the noncompliance of patients with different levels of resistance of Mtb to these drugs has worsened the situation. Previously developed anti-TB drugs targeted the replication machinery, protein synthesis, and cell wall biosynthesis pathways of Mtb. Therefore, novel drugs targeting alternate pathways crucial for the survival and pathogenesis of Mtb in the human host are needed. The genome of Mtb encodes three β-carbonic anhydrases (CAs) that are fundamental for pH homeostasis, hypoxia, survival, and pathogenesis. Recently, several studies have shown that the β-CAs of Mtb could be inhibited both in vitro and in vivo using small chemical molecules, suggesting that these enzymes could be novel targets for developing anti-TB compounds that are devoid of resistance by Mtb. In addition, homologs of β-CAs are absent in humans; therefore, drugs developed to target these enzymes might have minimal off-target effects. In this work, we describe the roles of β-CAs in Mtb and discuss bioinformatics and cheminformatics tools used in development and discovery of novel inhibitors of these enzymes. In addition, we summarize the in vitro and in vivo studies demonstrating that the β-CAs of Mtb are indeed druggable targets.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"343-381"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helicobacter pylori CAs inhibition. 幽门螺旋杆菌 CAs 抑制剂。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-06-08 DOI: 10.1016/bs.enz.2024.05.013
Bianca Laura Bernardoni, Concettina La Motta, Simone Carradori, Ilaria D'Agostino

Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC: 4.2.1.1) from Hp, namely HpαCA and HpβCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.

幽门螺旋杆菌(Hp)感染危及全球公共卫生安全,因为它极易引发严重疾病,如消化性溃疡、胃癌、糖尿病和心血管疾病。由于(多重)耐药性表型的增加,目前的疗法越来越不奏效,因此迫切需要具有创新作用机制的新型抗菌剂。在最有希望的药理靶点中,来自 Hp 的碳酸酐酶(EC:4.2.1.1),即 HpαCA 和 HpβCA,因其高可药性和在病原体在宿主体内生存的关键作用而崭露头角。因此,在过去的几十年中,这两种同工酶被分离出来并进行了表征,为研究它们的动力学和测试不同系列的抑制剂提供了机会。
{"title":"Helicobacter pylori CAs inhibition.","authors":"Bianca Laura Bernardoni, Concettina La Motta, Simone Carradori, Ilaria D'Agostino","doi":"10.1016/bs.enz.2024.05.013","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.05.013","url":null,"abstract":"<p><p>Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC: 4.2.1.1) from Hp, namely HpαCA and HpβCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"213-241"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial β-carbonic anhydrases. 细菌β-碳酸酐酶。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 Epub Date: 2024-08-16 DOI: 10.1016/bs.enz.2024.05.009
Marta Ferraroni

β-Carbonic anhydrases (β-CA; EC 4.2.1.1) are widespread zinc metalloenzymes which catalyze the interconversion of carbon dioxide and bicarbonate. They have been isolated in many pathogenic and non-pathogenic bacteria where they are involved in multiple roles, often related to their growth and survival. β-CAs are structurally distant from the CAs of other classes. In the active site, located at the interface of a fundamental dimer, the zinc ion is coordinated to two cysteines and one histidine. β-CAs have been divided in two subgroups depending on the nature of the fourth ligand on the zinc ion: class I have a zinc open configuration with a hydroxide ion completing the metal coordination, which is the catalytically active species in the mechanism proposed for the β-CAs similar to the well-known of α-CAs, while in class II an Asp residue substitute the hydroxide. This latter active site configuration has been showed to be typical of an inactive form at pH below 8. An Asp-Arg dyad is thought to play a key role in the pH-induced catalytic switch regulating the opening and closing of the active site in class II β-CAs, by displacing the zinc-bound solvent molecule. An allosteric site well-suited for bicarbonate stabilizes the inactive form. This bicarbonate binding site is composed by a triad of well conserved residues, strictly connected to the coordination state of the zinc ion. Moreover, the escort site is a promiscuous site for a variety of ligands, including bicarbonate, at the dimer interface, which may be the route for bicarbonate to the allosteric site.

β-碳酸酐酶(β-CA;EC 4.2.1.1)是一种广泛存在的锌金属酶,可催化二氧化碳和碳酸氢盐的相互转化。在许多病原菌和非病原菌中都分离出了这种酶,它们发挥着多种作用,通常与细菌的生长和存活有关。β-CAs 在结构上与其他类别的 CAs 有很大区别。在位于基本二聚体界面的活性位点上,锌离子与两个半胱氨酸和一个组氨酸配位。根据锌离子上第四配位体的性质,β-CAs 被分为两个亚类:第一类具有锌开放构型,由氢氧根离子完成金属配位,在为β-CAs 提出的机制中,它是催化活性物种,类似于众所周知的 α-CAs;而在第二类中,一个 Asp 残基取代了氢氧根离子。后一种活性位点构型已被证明是 pH 值低于 8 时无活性的典型形式。人们认为,Asp-Arg 二元在 pH 值诱导的催化转换中起着关键作用,通过置换锌结合的溶剂分子,调节第二类 β-CAs 活性位点的打开和关闭。一个非常适合碳酸氢盐的异构位点稳定了非活性形式。这个碳酸氢盐结合位点由三个保守的残基组成,与锌离子的配位状态密切相关。此外,在二聚体界面上,护送位点是包括碳酸氢盐在内的多种配体的杂交位点,这可能是碳酸氢盐进入异构位点的途径。
{"title":"Bacterial β-carbonic anhydrases.","authors":"Marta Ferraroni","doi":"10.1016/bs.enz.2024.05.009","DOIUrl":"https://doi.org/10.1016/bs.enz.2024.05.009","url":null,"abstract":"<p><p>β-Carbonic anhydrases (β-CA; EC 4.2.1.1) are widespread zinc metalloenzymes which catalyze the interconversion of carbon dioxide and bicarbonate. They have been isolated in many pathogenic and non-pathogenic bacteria where they are involved in multiple roles, often related to their growth and survival. β-CAs are structurally distant from the CAs of other classes. In the active site, located at the interface of a fundamental dimer, the zinc ion is coordinated to two cysteines and one histidine. β-CAs have been divided in two subgroups depending on the nature of the fourth ligand on the zinc ion: class I have a zinc open configuration with a hydroxide ion completing the metal coordination, which is the catalytically active species in the mechanism proposed for the β-CAs similar to the well-known of α-CAs, while in class II an Asp residue substitute the hydroxide. This latter active site configuration has been showed to be typical of an inactive form at pH below 8. An Asp-Arg dyad is thought to play a key role in the pH-induced catalytic switch regulating the opening and closing of the active site in class II β-CAs, by displacing the zinc-bound solvent molecule. An allosteric site well-suited for bicarbonate stabilizes the inactive form. This bicarbonate binding site is composed by a triad of well conserved residues, strictly connected to the coordination state of the zinc ion. Moreover, the escort site is a promiscuous site for a variety of ligands, including bicarbonate, at the dimer interface, which may be the route for bicarbonate to the allosteric site.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"65-91"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Enzymes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1